跳至主要内容
临床试验/ACTRN12622000339752
ACTRN12622000339752招募中未知

A randomised, sham controlled clinical trial using Transcranial Direct Current Stimulation for Post-Traumatic Stress Disorder

Austin Health0 个研究点目标入组 50 人开始时间: 2022年2月24日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
Austin Health
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Admitted to hospital
  • Clinical diagnosis of PTSD by Consultant Psychiatrist
  • Capacity for consent
  • PCL-5 score above 50

排除标准

  • Presence of metallic objects in or around the head
  • Medical disorder such as epilepsy or head injury
  • High suicide risk (measured by standard Risk Assessment, requiring hourly or greater observation)

研究者

发起方
Austin Health

相似试验

招募中
不适用
The Acupause study: Acupuncture for postmenopausal hot flushesPostmenopausal vasomotor symptomsReproductive Health and Childbirth - Menstruation and menopauseAlternative and Complementary Medicine - Other alternative and complementary medicine
ACTRN12611000393954niversity of Melbourne360
尚未招募
3 期
SLeep Evaluation and Effectiveness Protocol for Intensive Care Units (SLEEP-ICU)Delirium
ACTRN12624000991516South Metropolitan Health Service72
已完成
不适用
The Efficacy of Caralluma for Anxiety in AdultsStressMental Health - AnxietyAlternative and Complementary Medicine - Herbal remediesAnxiety
ACTRN12616000741482RDC Global117
已完成
3 期
A randomised, controlled clinical trial assessing the efficacy of;Lanreotide to halt disease progression in ADPKDpolycystic kidney disease100383601001965410029149Autosomal Dominant Polycystic Kidney Disease
NL-OMON39497niversitair Medisch Centrum Groningen300
进行中(未招募)
不适用
To investigate the effect of Lanreotide on renal function decline in ADPKD patientsFirst, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume.MedDRA version: 14.1Level: LLTClassification code 10023433Term: Kidney polycysticSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2011-005017-37-NLDIPAK Consortium